

A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of Exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease.

[Redacted Signature]

DocuSigned by:
[Redacted Signature]



DocuSigned by:
[Redacted Signature]

[Redacted Signature]



Éî€̀ĐḡÍıĬÉıJFıİıFıÉıĀDÄĒÄĒÈÈÈĀBÉÁĀÄĒÄÈCĀBCÈÉĀCĀCĀBBĀĀÉĀ

Éî€̀ĐḡÍıĬÉıJfıİıFıÉıĀDÄĒÄĒÈÈÈĀBÉÁĀÄĒÄÈCĀBCÈÉĀCĀCĀBBĀĀÉĀ

	<hr/> <hr/> <hr/>
	<hr/> <hr/> <hr/>
	<hr/> <hr/> <hr/>

Éî€̀ĐḡÍıĬÉıJfıİıFıÉıĀDÄĒÄĒÈÈÈĀBÉÁĀÄĒÄÈCĀBCÈĒĀCĀBBĀĀÉĀ





Exenatide-PD3

Éî€̀ĐḡÍıĬÉıJfıİıFıÉıĀDÄĒÄĒÈÈÈĀBÉÁĀÄĒÄÈCĀBCÈĒĀCĀBBĀĀÉĀ

4. Exenatide /GLP-1 receptor stimulation increases neurogenesis in the subventricular zone.

5. GLP-1 receptor agonists enhance synaptic plasticity.

6. GLP-1 receptor agonists reduce neuroinflammation through an action on microglia.

Éî€ìÐ:GíAÉÍJFíîF#ÉÇ#ÀDÀÉÄÈÈÈ#ÀBÉÁ#ÄÈÄÈ#CÄBC#ÉÄCÄCÄBBÄÄÉÁ

Exenatide-PD3

Bydureon

6.1.2.1 Principal Investigator's (PI) Qualifications and Agreements

6.1.2.2 Resourcing at site

6.3.1.1 Participant selection

6.3.1.3 Participant Exclusion Criteria

Éî€̀ĐḡÍıĬÉıJfıİıFıÉıĀDÄĒÄĒÈÈÈĀBÉÁĀÄĒÄÈCĀBCÈĒĀCĀBBĀĀÉĀ

Éî€̀ĐḡÍıĬÉıJfıİıFıÉıĀDÄĒÄĒÈÈÈĀBÉÁĀÄĒÄÈCĀBCÈÉĀCĀCĀBBĀĀÉÁ

Éî€ìÐ:GíAÉÍJFíîFñÉÇÀDÀÄÄÈÄÈÈÀBÉÁÄÄÄÈÈCÄBCÈÄÄCÄCÄBBÄÄÄ

Exenatide-PD3

Éî€̀ĐḡÍıĬÉıJFıİıFıÉıĀDÄĒÄĒÈÈÈĀBÉÁĀÄĒÄĒCĀBCĒÉĀCĀCĀBBĀĀÉĀ

6.11.3.1 Safety reporting

Adverse Event (AE)	
Adverse Reaction (AR)	
Unexpected Adverse Reaction (UAR)	

Éî€̀ĐḡÍıĬÉıJfııFıÉıĀDÄĒÄĒÈÈÈĀBÉÁĀÄĒÄÈCĀBCÈÉĀCĀBBĀĀÉĀ

6.11.3.4 *Other Notifiable Adverse Events*

6.11.3.5 *Procedures to follow in the event of female participants becoming pregnant*

screening
screening

6.4.5.2 Dose Interruptions
replaced by

6.6 Participant Timeline
Hauser Diary

Additional Point added

6.9.1.1 Sequence generation

Balancing factors added (research site and sub studies)

Changed to


11.5 Appendix 5 Proof-of-concept imaging sub-study- added.

is"

Éî€ìÐ:GíAÉÍJFíîF#ÉÇÀDÀÈÄÈÈÈ#ÀBÉÁ#ÄÈÄÈ#CÄBC#ÈÄCÄCÄBBÄÄÉÁ

Exenatide-PD3

Exenatide-



Éî€ìĐıGııÊıJFııFııÉııÁDÄÉÄÈÈÈÈÀBÉÁÄÄÄÈÈCÄBCÈÈÄCÄBBÄÄÉ

Exenatide

Drug	Conversion factor

11.2.2.1 UCLH Neurogenetics laboratory sample

11.2.3.1 Genetic analysis

11.

11.3.1

11.4.1

Certificate Of Completion

Envelope Id: 6B4F6F4E48D14F6F9789F293948832C1

Status: Completed

Subject: Please DocuSign: Exenatide-PD3 Protocol V4.0 22Feb2022_Clean(SampleAnalysisAdded).pdf

Source Envelope:

Document Pages: 95

Signatures: 4

Envelope Originator:

Certificate Pages: 5

Initials: 0

Grace Auld

AutoNav: Enabled

90 High Holborn 2nd Floor London

Enveloped Stamping: Enabled

, London WC1V 6LJ

Time Zone: (UTC) Dublin, Edinburgh, Lisbon, London

g.auld@ucl.ac.uk

IP Address: 128.40.216.117

Record Tracking

Status: Original

Holder: Grace Auld

Location: DocuSign

11 March 2022 | 14:50

g.auld@ucl.ac.uk

Signer Events


Signature

Timestamp

Gemma Jones

DocuSigned by:

gemma.jones@ucl.ac.uk



Sent: 11 March 2022 | 14:53

Viewed: 11 March 2022 | 16:07

Security Level: Email, Account Authentication (Optional)

Signed: 11 March 2022 | 16:07

Signature Adoption: Pre-selected Style

Using IP Address: 128.40.217.115

Electronic Record and Signature Disclosure:


Accepted: 11 March 2022 | 16:07

ID: 6224f590-dec1-40db-b138-8cc5d748af4b

Grace Auld

DocuSigned by:

g.auld@ucl.ac.uk



Sent: 11 March 2022 | 14:53

Viewed: 11 March 2022 | 14:53

Clinical Project Manager

Signed: 11 March 2022 | 14:54

UCL

Signature Adoption: Pre-selected Style

Security Level: Email, Account Authentication (Optional)

Using IP Address: 128.40.216.117

Electronic Record and Signature Disclosure:

Accepted: 11 December 2020 | 09:10

ID: 466abd10-76d4-42b0-ae04-2bd0f6ba7cd1

Nick Freemantle

DocuSigned by:

nicholas.freemantle@ucl.ac.uk



Sent: 11 March 2022 | 14:53

Viewed: 11 March 2022 | 14:54

Professor & Director

Signed: 11 March 2022 | 14:55

Comprehensive Clinical Trials Unit (CCTU) at UCL

Signature Adoption: Pre-selected Style

Security Level: Email, Account Authentication (Optional)

Using IP Address: 86.148.233.126

Electronic Record and Signature Disclosure:


Accepted: 22 September 2020 | 10:02

ID: fe2ae0ae-56f3-4f05-b488-9f99b0266d69

Tom Foltynie

DocuSigned by:

t.foltynie@ucl.ac.uk



Sent: 11 March 2022 | 14:53

Viewed: 11 March 2022 | 17:16

prof

Signed: 11 March 2022 | 17:16

Security Level: Email, Account Authentication (Optional)

Signature Adoption: Pre-selected Style

Using IP Address: 144.82.8.44

Electronic Record and Signature Disclosure:

Accepted: 11 March 2022 | 17:16

ID: 72305072-de2a-42fc-bc69-67ac50f89b9d

In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	11 March 2022 14:53
Certified Delivered	Security Checked	11 March 2022 17:16
Signing	11 March 2022 17:16	

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notices or disclosures, we will also provide (as far as required by 45 CFR 164.512(c)(4)-(6)) notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Comprehensive Clinical Trials Unit (CCTU) at UCL:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: t.lazenby@ucl.ac.uk

To advise Comprehensive Clinical Trials Unit (CCTU) at UCL of your new email address

